MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from
at-the-market offering, net of...
$38,902K
Proceeds from issuance of
common stock upon...
$1,698K
Net cash provided by
financing activities
$40,600K
Net increase in cash
and cash...
$2,585K
Canceled cashflow
$38,015K
Stock-based compensation
expense
$6,968K
Related party accounts
payable and other...
$2,995K
Prepaid expenses and
other current assets
-$461K
Non-cash lease expense
$143K
Depreciation expense
$43K
Proceeds from maturities
of marketable...
$76,470K
Net cash used in
operating activities
-$23,578K
Net cash (used in)
provided by investing...
-$14,437K
Canceled cashflow
$10,610K
Canceled cashflow
$76,470K
Net loss
-$31,820K
Purchases of marketable
securities
$90,834K
Accrued expenses and
other current...
-$1,304K
Accounts payable
-$493K
Net accretion of
premiums and discounts on...
$446K
Operating lease liability
-$125K
Purchases of property and
equipment
$73K
Back
Back
Cash Flow
Oruka Therapeutics, Inc. (ORKA)
Oruka Therapeutics, Inc. (ORKA)
source: myfinsight.com